Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet

NCT00541437 | Completed

• 1 other identifier: GBL L-13
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy and safety of type 2 diabetes patients switched from sulfonylurea co-administered with metformin to glyburide/metformin combination tablet. It is expected that safety and efficacy of GlucoMet® is not inferior to co-administration of sulfonylurea and metformin.

Conditions

Type 2 Diabetes Mellitus

Keywords

Change from baseline of HbA1c after 16 weeks of treatment; Change from baseline of FPG after 16 weeks of treatment; Change from baseline of diabetes self-care scale by patient on drug administration after 16 weeks of treatment

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female age between 20 to 75 years and were diagnosed with type-2 DM for a minimum of 4 months before baseline.
• Maintain stable dose of sulfonylurea and metformin co-administered 4 months before baseline.
• Consider suitable to switch from current therapeutic dose to one of the eight testing regimens.
• FPG of 80-200mg/dl at screening visit
• % ≦ HbA1c ≦ 9% at screening visit, and change of HbA1c ≦ 1% within 12 weeks before screening visit.
• The body index must be between 18.5 and 35 Kg/m2 at screening visit.
• Sign and date the Informed Consent Form

You may not qualify if:

• Renal disease or renal dysfunction (e.g. serum creatinine \> 1.5mg/dl)
• Currently significant GI disorder (such as peptic ulcer or diarrhea requiring chronic medical treatment) or which may interfere with absorption of the study drugs.
• History or concurrent liver disease or hepatic impairment (total bilirubin above upper normal limit, ALT or AST above 2.5 times of upper normal limit at screening visit.)
• Acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis, with or without coma.
• History of cardiovascular collapse (shock) or congestive heart failure (function class III to IV).
• History of stroke, myocardial infarction, coronary revascularization, or arrhythmia that requires medical treatment, within past 6 months.
• Having proliferative retinopathy.
• Current acute infection, including systemic infection with fever and/or sepsis, or pulmonary infection, cellulitis, etc.
• Having been treated with insulin during past 6 months, or treated with acarbose or glitazones with change of daily dose past 4 months.
• Seriously dehydrated.
• History of alcoholism (all the time or short-term heavy drinking) or drug abuse, or taking other investigational drug.
• Pregnant or breast feeding women or planning a pregnancy.
• Having a surgery within 4 weeks prior to entering the study or a history of cancer within five years.
• Known hypersensitive to glyburide or metformin hydrochloride.
• Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.

Sponsors & Collaborators

• Genovate Biotechnology Co., Ltd.,: lead

Study Sites (1)

National Taiwan university hospital

Taipei, Taiwan

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Tien-Shang Huang, M.D

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 8, 2007
• First Posted: October 10, 2007
• Study Start: May 1, 2006
• Study Completion: February 1, 2007
• Last Updated: October 10, 2007

Record last verified: 2007-10

Locations

TW (1)